P450

Systemic Bio to Present Innovative Human-relevant Datasets from h-VIOS™ Platform at SOT and AACR 2024 Annual Meetings

Retrieved on: 
Thursday, February 8, 2024
Abstract, Society of Toxicology, DMPK, Therapy, 3D Systems, CYP, AACR, SOT, Liver injury, Tissue, Liver, Urea, Research, P450, Annual general meeting

HOUSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Systemic Bio™ , a 3D Systems (NYSE:DDD) company, is excited to announce the acceptance of two abstracts for presentation at the prestigious Society of Toxicology (SOT) 2024 Annual Meeting (Salt Lake City, March 10-14, 2024) and American Association for Cancer Research (AACR) 2024 Annual Meeting (San Diego, April 5-10, 2024).

Key Points: 
  • HOUSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Systemic Bio™ , a 3D Systems (NYSE:DDD) company, is excited to announce the acceptance of two abstracts for presentation at the prestigious Society of Toxicology (SOT) 2024 Annual Meeting (Salt Lake City, March 10-14, 2024) and American Association for Cancer Research (AACR) 2024 Annual Meeting (San Diego, April 5-10, 2024).
  • At the SOT 2024 meeting, Systemic Bio will present its latest research on an advanced liver model that demonstrates several-fold enhanced albumin production, CYP (cytochrome P450) activity, and urea production compared to traditional models.
  • The second abstract, accepted for AACR 2024, showcases a novel model that simultaneously assesses on-target anti-tumor therapeutic efficacy and off-target liver injury of therapeutics across different modalities.
  • To delve deeper into this research, all conference attendees and fellow researchers can visit booth #4452 to engage directly with Systemic Bio’s team and discover the full potential of the h-VIOS platform.

SiFive’s New High-Performance Processors Offer a Significant Upgrade for Wearable and Consumer Products

Retrieved on: 
Tuesday, November 1, 2022
Electronic Design Automation, Semiconductor, Security, Technology, Software, Hardware, Qualcomm, AOSP, MSI, Leadership, Vector Unit, Efficiency, Conference, AP, Roadmap, Time, Vector, Product management, AIA, Industry, Android (operating system), P450, Innovation, Attention, ISAS, Technology, AR, VP, Artificial intelligence, Machine learning, IP, Robotics, Solution, Antirrhinum, Video game console, Mobile phone, SiFive

The modern and innovative SiFive design methodologies bring raw compute density that is a substantial advantage for SiFive Performance products and also translates into significant cost savings for customers.

Key Points: 
  • The modern and innovative SiFive design methodologies bring raw compute density that is a substantial advantage for SiFive Performance products and also translates into significant cost savings for customers.
  • The P670 and P470 are specifically designed for, and capable of handling the most demanding workloads for wearables and other advanced consumer applications.
  • These new products offer powerful performance and compute density for companies looking to upgrade from legacy ISAs, said Chris Jones, SiFive VP of Product.
  • "Samsungs System LSI Business holds a wide portfolio of solutions for various applications, such as mobile, wearables and other consumer devices.

Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster

Retrieved on: 
Friday, June 3, 2022
MAD, HIV disease progression rates, Hematology, Plasma, Weight loss, Omicron, Pain, SAD, BID, Autoimmune disease, Severe acute respiratory syndrome coronavirus 2, Cancer, U.S. Securities and Exchange Commission, P450, Infection, Pharmacokinetics, Forward-looking statement, Ritonavir, CEO, GLP, Cathepsin L, TRPV1, Trial of the century, Phase, Dog, Mouse, Antibody, IC50, EUA, CYP, RTX, Annual report, Cathepsin, Sciatica, Security (finance), Liver, Metabolism, Vaccine, Patient, Private Securities Litigation Reform Act, PHN, Postherpetic neuralgia, CYP3A4, API, RATS, FDA, Therapy, GLOBE, Risk, SAN, Osteoarthritis, Safety, Pharmaceutical industry, Generic drug, COVID-19

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro)inhibitor, STI-1558.

Key Points: 
  • SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro)inhibitor, STI-1558.
  • The world has been experiencing repeated waves of infection of SARS-CoV-2 and its continually emerging variants.
  • Oral antiviral drugs with broad-spectrum antiviral activities and limited potential for drug-drug interaction risks are still urgently needed.
  • ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc.
    All other trademarks are the property of their respective owners.

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, January 14, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Janus, Atopic dermatitis, New Drug Application, NDA, Patient, Food and Drug Administration, Week, Janus kinase 1, Pfizer, Dupilumab, Inc., Psoriasis Area and Severity Index, NYSE, Rash, Common, Adult, Nausea, CEO, JADE, Disease, Kidney failure, CYP2C19, AD, Department, George Washington University School of Medicine & Health Sciences, Headache, PFE, Inflammation, Outline of health sciences, Skin, Pain, JAK1, CYP, MD, Dermatitis, Food, Immunology, FDA, EASI, MPH, IGA, Pharmaceutical industry, P450, Safety, Doctor of Philosophy, CIBINQO, Atopic Dermatitis, Pfizer Inflammation & Immunology, CIBINQO, ATOPIC DERMATITIS, PFIZER INFLAMMATION & IMMUNOLOGY

Atopic dermatitis is so much more than just a rash, and it goes beyond the surface of the skin.

Key Points: 
  • Atopic dermatitis is so much more than just a rash, and it goes beyond the surface of the skin.
  • We appreciate Pfizers commitment to this resilient patient community and eagerly await the positive impact CIBINQO could have on the treatment landscape for moderate-to-severe atopic dermatitis.
  • Five clinical trials in the CIBINQO JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program were included in the New Drug Application (NDA) to support the FDA approval.
  • Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population.